Clinical Trials · NCT02976740
SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- The First Affiliated Hospital of Xiamen University
- Enrollment
- 48
- Start date
- Nov 2016
- Locations
- 1 site, China
- Primary endpoint
- abscopal effect rate